| Information regarding our geographic activities |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For three months ended
September 30, |
|
|
For the nine months ended
September 30, |
|
|
(In thousands)
|
|
2012 |
|
|
2011 |
|
|
2012 |
|
|
2011 |
|
|
Operating loss from continuing operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
$ |
(5,593 |
) |
|
$ |
(262 |
) |
|
$ |
(17,053 |
) |
|
$ |
(3,601 |
) |
|
Corporate
|
|
|
(3,776 |
) |
|
|
(5,542 |
) |
|
|
(10,504 |
) |
|
|
(11,113 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$ |
(9,369 |
) |
|
$ |
(5,804 |
) |
|
$ |
(27,557 |
) |
|
$ |
(14,714 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
$ |
2,618 |
|
|
$ |
997 |
|
|
$ |
7,315 |
|
|
$ |
2,731 |
|
|
Corporate
|
|
|
44 |
|
|
|
43 |
|
|
|
132 |
|
|
|
127 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$ |
2,662 |
|
|
$ |
1,040 |
|
|
$ |
7,447 |
|
|
$ |
2,858 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
United States
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
Chile
|
|
|
6,781 |
|
|
|
5,356 |
|
|
|
19,669 |
|
|
|
17,545 |
|
|
Spain
|
|
|
1,997 |
|
|
|
— |
|
|
|
1,997 |
|
|
|
— |
|
|
Israel
|
|
|
1,516 |
|
|
|
— |
|
|
|
4,661 |
|
|
|
— |
|
|
Mexico
|
|
|
1,201 |
|
|
|
1,404 |
|
|
|
3,724 |
|
|
|
4,568 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
$ |
11,495 |
|
|
$ |
6,760 |
|
|
$ |
30,051 |
|
|
$ |
22,113 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
As of |
|
|
(In thousands)
|
|
September 30,
2012 |
|
|
December 31,
2011 |
|
|
Assets:
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
$ |
198,483 |
|
|
$ |
154,437 |
|
|
Corporate
|
|
|
51,539 |
|
|
|
75,048 |
|
|
Discontinued operations
|
|
|
— |
|
|
|
4 |
|
| |
|
|
|
|
|
|
|
|
| |
|
$ |
250,022 |
|
|
$ |
229,489 |
|
| |
|
|
|
|
|
|
|
|
|